Jamestown’s Post

We are excited to share that Boehringer Ingelheim has acquired its fourth license from ALSA’s portfolio company Oxford BioTherapeutics for the development of novel antibody-based cancer treatments. This significant milestone underscores the strategic value of OBT's proprietary OGAP® discovery platform.   Congratulations to the teams at Oxford BioTherapeutics and Boehringer Ingelheim for this impressive step forward. At ALSA Ventures, we remain committed to empowering bold ideas that deliver value to patients, partners, and investors alike.   Read full story here:   #BiotechInnovation #Oncology #AntibodyTherapeutics #LifeSciences #VentureCapital

New blog post on “Trends and Challenges in Oncology Drug Development” from my talented colleague Louise Scott PhD and Catalyst Oncology

Oncology is the largest therapeutic area in drug development and is expected to grow as new cancer cases are projected to increase.  At Catalyst Oncology, we are at the forefront of this evolving landscape. Learn more about the growing market size and the future of cancer treatment in the blog post “Trends and Challenges in Oncology Drug Development,” featuring insights from Louise Scott PhD. https://lnkd.in/dwZdVf8X #OncologyDrugDevelopment #OncologyResearchTrends #OncologyResearchChallenges #CancerTreatments #Biotech 

BCBN Feed: Lilly to pay $2.5B for Boston biotech’s lead cancer drug https://lnkd.in/gshnwGsv Eli Lilly and Co., which cemented its place in Boston last year with the opening of a new research and development center, is now buying a cancer program from a Boston biotech. ... [...]

Founded in 2022 by Athena Countouriotis MD, and Mohammad Hirmand, Avenzo Therapeutics, a clinical-stage biotech, has secured $386M in Series A/A-1 financing to advance its oncology pipeline. This includes an exclusive option agreement with VelaVigo for a potential first-in-class cancer therapy. More at: https://lnkd.in/eb2CTcBY #Oncology #Biotech #Funding #Healthcare

🌟 Exciting Partnership Announcement 🌟 DeepLife is incredibly proud to be part of the PAN-CKI Consortium, led by #CasInventPharma, alongside our esteemed partners #Alveolix and the University of Bern. This collaboration has just secured a €4M Eurostars grant to drive forward groundbreaking research on a novel Casein Kinase 1 Inhibitor (CK1) for the treatment of pancreatic cancer. 🎉 Pancreatic cancer is one of the most aggressive and challenging diseases to treat, and we believe that the innovative approach being developed within the PAN-CKI Consortium could be a true game-changer. Combining cutting-edge AI/ML technology with advanced organoid and organ-on-chip systems, we are aiming to deliver new treatment options that can provide hope to patients who need it the most. 💡 At #DeepLife, we are committed to harnessing the power of AI to accelerate the discovery of life-saving therapies, and we are optimistic about advancing this CK1 inhibitor to improve outcomes for pancreatic cancer patients worldwide. Together with CasInvent, Alveolix, and the University of Bern, we are thrilled to contribute to this vital mission and push the boundaries of what’s possible in oncology treatment. 🧬 If you want to know more about partnership opportunities, contact us at partnerships@deeplife.co #DeepLife #PANCKIConsortium #PancreaticCancer #AI #Innovation #Biotech #digitaltwinofcells #CancerResearch #Collaboration #HealthTech #CaseinKinase1 #Eurostars #HealthcareTransformation 

Exciting news in oncology! 🧬 Eli Lilly has announced a $2.5 billion acquisition of an experimental cancer drug from Scorpion Therapeutics. This game-changing move highlights Lilly's dedication to precision oncology and tackling unmet needs in cancer treatment. Their new drug, STX-478, holds incredible promise—and this acquisition could shape the future of the oncology field. 🌟 Want to learn more? Check out our latest blog post through the link in the comments. 💊 #CancerTreatment #Innovation #Oncolog

Big news in oncology today! 🎉 Scorpion Therapeutics has just closed a $150 million Series C financing! 💰 This round was co-led by Frazier Life Sciences and Lightspeed Venture Partners, with significant contributions from existing and new investors. The funding will propel the mid-stage development of STX-478, a potentially groundbreaking treatment for breast cancer and other solid tumors. STX-478 shows great promise as a mutant-selective PI3Kα inhibitor. This could revolutionise treatment options for patients with PI3Kα mutations, a common driver of cancer. Scorpion's pipeline is robust, driven by an integrated small molecule discovery engine that's second to none. This financing will also support advancing their EGFR inhibitor franchise and next-gen precision oncology therapies. #Oncology #PrecisionMedicine #LifeSciences #CancerResearch #Investment

Harnessing the power of Antibody Drug Conjugates (ADCs) to treat cancer! 🦠 Spirea, founded by Cambridge nanoscientist Myriam Ouberai, is developing next-generation ADCs to treat hard-to-treat cancers. Their ADCs precisely target and kill cancer cells while sparing healthy ones, enhancing drug efficacy by attaching more drug to each antibody. In 2020, Spirea raised £2.4 million in a funding round co-led by Cambridge Enterprise Ventures and Jonathan Milner, with contributions from other investors. This investment supports Spirea's mission to develop more effective ADCs and reduce side effects, advancing cancer treatment. To find out more about Spirea’s ADC technology, click here: https://lnkd.in/eFHypAgM #ChangingTheStoryOfCancer #CambridgeInnovation

Don’t expect to be Michael Phelps when you’re new to oncology Instead, put on your pool floaties and focus on not swallowing too much water 😉 --- 📌 When you’re ready to learn how to swim, the Enjoy Learning Oncology (ELO) program can accelerate your growth in oncology. Check it out 👉 https://lnkd.in/gTRvKSQS I’m the Kelley in KelleyCPharmD 👋 and I help pharmacists learn the complex world of oncology #LearnOncology #Pharmacists #OncologyPharmacists #Oncology